NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring BRAF V600 Mutations

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 25 Oct 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Vemurafenib (Primary)
Indications CNS cancer; Ependymoma; Ewing's sarcoma; Glioma; Langerhans cell histiocytosis; Liver cancer; Neuroblastoma; Neuroectodermal tumours; Non-Hodgkin's lymphoma; Osteosarcoma; Rhabdoid tumour; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours; Wilms' tumour
Focus Therapeutic Use
Acronyms Pediatric MATCH

28 Sep 2024 Planned End Date changed from 22 Sep 2024 to 22 Sep 2025.
05 Aug 2024 Status changed from recruiting to discontinued, according to Results published in the Oncologist.
05 Aug 2024 Results published in the Oncologist.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com